These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 25850965)

  • 1. Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome.
    Fanciullino R; Mercier C; Serdjebi C; Berda Y; Fina F; Ouafik L; Lacarelle B; Ciccolini J; Costello R
    Pharmacogenet Genomics; 2015 Jun; 25(6):317-21. PubMed ID: 25850965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.
    Mahfouz RZ; Jankowska A; Ebrahem Q; Gu X; Visconte V; Tabarroki A; Terse P; Covey J; Chan K; Ling Y; Engelke KJ; Sekeres MA; Tiu R; Maciejewski J; Radivoyevitch T; Saunthararajah Y
    Clin Cancer Res; 2013 Feb; 19(4):938-48. PubMed ID: 23287564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs.
    Serdjebi C; Milano G; Ciccolini J
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):665-72. PubMed ID: 25495470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients.
    Donnette M; Hamimed M; Ciccolini J; Sicard G; Correard F; Farnault L; Ouafik L; Venton G; Fanciullino R
    Br J Haematol; 2023 Nov; 203(4):625-636. PubMed ID: 37691342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine.
    Fanciullino R; Farnault L; Donnette M; Imbs DC; Roche C; Venton G; Berda-Haddad Y; Ivanov V; Ciccolini J; Ouafik L; Lacarelle B; Costello R
    Blood Adv; 2018 Mar; 2(5):462-469. PubMed ID: 29490977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation.
    Mercier C; Raynal C; Dahan L; Ortiz A; Evrard A; Dupuis C; Blesius A; Duluc M; Franceschini F; Giacometti S; Salas S; Milano G; Favre R; Seitz JF; Ciccolini J
    Pharmacogenet Genomics; 2007 Oct; 17(10):841-4. PubMed ID: 17885621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies.
    Ciccolini J; Dahan L; André N; Evrard A; Duluc M; Blesius A; Yang C; Giacometti S; Brunet C; Raynal C; Ortiz A; Frances N; Iliadis A; Duffaud F; Seitz JF; Mercier C
    J Clin Oncol; 2010 Jan; 28(1):160-5. PubMed ID: 19933910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoprotection against cytosine nucleoside analogs using the human cytidine deaminase gene.
    Eliopoulos N; Beauséjour C; Momparler RL
    Prog Exp Tumor Res; 1999; 36():124-42. PubMed ID: 10386070
    [No Abstract]   [Full Text] [Related]  

  • 9. FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients.
    Serdjebi C; Gagnière J; Desramé J; Fein F; Guimbaud R; François E; André T; Seitz JF; Montérymard C; Arsene D; Volet J; Abakar-Mahamat A; Lecomte T; Guerin-Meyer V; Legoux JL; Deplanque G; Guillet P; Ciccolini J; Lepage C; Dahan L
    PLoS One; 2015; 10(8):e0135907. PubMed ID: 26308942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine.
    Raynal C; Ciccolini J; Mercier C; Boyer JC; Polge A; Lallemant B; Mouzat K; Lumbroso S; Brouillet JP; Evrard A
    Ther Drug Monit; 2010 Feb; 32(1):53-60. PubMed ID: 20010457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.
    Cohen R; Preta LH; Joste V; Curis E; Huillard O; Jouinot A; Narjoz C; Thomas-Schoemann A; Bellesoeur A; Tiako Meyo M; Quilichini J; Desaulle D; Nicolis I; Cessot A; Vidal M; Goldwasser F; Alexandre J; Blanchet B
    Br J Clin Pharmacol; 2019 Jun; 85(6):1227-1238. PubMed ID: 30701582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yin and yang of cytidine deaminase roles in clinical response to azacitidine in the elderly: a pharmacogenetics tale.
    Fanciullino R; Mercier C; Serdjebi C; Venton G; Colle J; Fina F; Ouafik L; Lacarelle B; Ciccolini J; Costello R
    Pharmacogenomics; 2015 Nov; 16(17):1907-12. PubMed ID: 26556583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy.
    Ding X; Chen W; Fan H; Zhu B
    Gene; 2015 Mar; 559(1):31-7. PubMed ID: 25582275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile.
    Mercier C; Dupuis C; Blesius A; Fanciullino R; Yang CG; Padovani L; Giacometti S; Frances N; Iliadis A; Duffaud F; Ciccolini J
    Cancer Chemother Pharmacol; 2009 May; 63(6):1177-80. PubMed ID: 19107485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients.
    Ueno H; Kaniwa N; Okusaka T; Ikeda M; Morizane C; Kondo S; Sugiyama E; Kim SR; Hasegawa R; Saito Y; Yoshida T; Saijo N; Sawada J
    Br J Cancer; 2009 Mar; 100(6):870-3. PubMed ID: 19293806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen.
    Serdjebi C; Seitz JF; Ciccolini J; Duluc M; Norguet E; Fina F; Lacarelle B; Ouafik L; Dahan L
    Pharmacogenomics; 2013 Jul; 14(9):1047-51. PubMed ID: 23837479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recipient/donor contradictory genotypes with impact on drug pharmacogenetics after liver transplant: a deadly gift?
    Serdjebi C; Ciccolini J; Fina F; Delarue A; Verschuur A; Lacarelle B; Ouafik L; André N
    Pharmacogenet Genomics; 2014 Oct; 24(10):527-9. PubMed ID: 25003625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
    Grövdal M; Karimi M; Khan R; Aggerholm A; Antunovic P; Astermark J; Bernell P; Engström LM; Kjeldsen L; Linder O; Nilsson L; Olsson A; Holm MS; Tangen JM; Wallvik J; Oberg G; Hokland P; Jacobsen SE; Porwit A; Hellström-Lindberg E
    Br J Haematol; 2010 Aug; 150(3):293-302. PubMed ID: 20497178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin.
    Yonemori K; Ueno H; Okusaka T; Yamamoto N; Ikeda M; Saijo N; Yoshida T; Ishii H; Furuse J; Sugiyama E; Kim SR; Kikura-Hanajiri R; Hasegawa R; Saito Y; Ozawa S; Kaniwa N; Sawada J
    Clin Cancer Res; 2005 Apr; 11(7):2620-4. PubMed ID: 15814642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
    Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
    Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.